Fresh on the heels of its Phase III disaster with the Alzheimer's drug Flurizan, Myriad Genetics announced that it has brought in JPMorgan Chase to help it conduct a strategic review. The developer is considering a split of its molecular diagnostics business and pharma development operations. Myriad had $65.5 million on hand June 30, largely from the $100 million upfront fee it collected from H. Lundbeck for Flurizan. Lundbeck reported a 52 percent drop in second quarter profits after writing off Flurizan.
--read the report in the Wall Street Journal